**Supplemental Digital Content**

**Table S1. Description of the study population**

|  |  |  |
| --- | --- | --- |
| **Characteristics** | At first biopsy(N=31) | At second biopsy(N=7) |
| **Demographics** |  |  |
| Male:female ratio (% male)  | 28/3 (90.3) | 6/1 (85.7) |
| Age, years† | 42 (37 – 53) | 43 (37 – 45) |
| From zone of high HBV-endemicity | 3 (9.7) | 1 (14.3) |
| **HIV-related characteristics** |  |  |
| Time since first HIV-positive test, years†  | 12.0 (6.8 – 16.6) | 12.7 (4.1 – 18.1) |
| Ever having an AIDS-defining illness | 8 (25.8) | 7 (100) |
| CD4+ cell count, /mm3† | 448 (331 – 641) | 632 (539 – 1201) |
| Nadir CD4+ cell count, /mm3† | 262 (150 – 326) | 262 (179 – 431) |
| ART-naïve | 2 (6.5) | 0 ( 0) |
| Detectable HIV-RNA (>50 copies/mL) | 6 (19.4) | 2 (28.6) |
|  HIV-RNA viral load, log10 copies/mL†\*  | 3.5 (2.9 – 4.6) | 3.1 (2.1 – 4.1) |
| Duration of ART, years†\*\*  | 8.3 (5.9 – 10.0) | 8.9 (3.6 – 11.1) |
| **HBV-related characteristics** |  |  |
| Time since first HBsAg-positive test, years†  | 10.4 (6.9 – 15.3) | 12.6 (4.0 – 16.1) |
| HBeAg-positive | 22 (71.0) | 4 (57.1) |
| Detectable HBV-DNA (≥60 IU/mL) HBV-DNA viral load, log10 copies/mL†¥ | 22 (71.0)3.1 (2.7 – 7.1) | 1 (14.3)2.9¶ |
| ALT (IU/mL) † | 35 (27 – 49) | 27 (19 – 53) |
| Concomitant anti-HBV exposure |  |  |
|  LAM | 21 (67.7) | 4 (57.1) |
|  TDF | 17 (54.8) | 7 (100) |
|  ADV | 2 (6.5) | 0 (0) |
| Previous anti-HBV exposure |  |  |
|  LAM | 28 (90.3) | 6 (85.7) |
|  TDF | 14 (45.2) | 7 (100) |
|  ADV | 5 (16.1) |  1 (14.3) |
|  IFN | 10 (32.3) | 2 (28.6) |
|  PEG-IFN | 2 (6.5) | 0 (0) |
| HBV genotype  | [*N*=17] | [*N*=1] |
|  A | 11 (64.7) | 1 (100) |
|  D | 1 (5.9) | 0 (0) |
|  E | 1 (5.9) | 0 (0) |
|  G | 4 (23.5) | 0 (0) |
| Precore mutation | [*N*=17] | [*N*=1] |
|  Present Absent | 3 (17.6)14 (82.4) | 0 (0)1 (100) |
| METAVIR fibrosis levels |  |  |
|  F3-F4 | 9 (29.0) | 0 (0) |
|  F2 | 10 (32.3) | 3 (42.9) |
|  F0-F1 | 12 (38.7) | 4 (57.1) |
| Anti-HCV positive | 1 (3.2) | 0 (0) |

ADV, adefovir; ALT, alanine aminotransferase; ART, antiretroviral therapy; cccDNA, covalently-closed circular DNA; HBV, hepatitis B virus; HCV, hepatitis C virus; IFN, interferon; LAM, lamivudine; TDF, tenofovir; PEG-IFN, pegylated interferon.

All statistics are n (%), however those with (†) indicate median (IQR). Time from first to second biopsy was a median 44.0 months (range = 36.7 – 47.1) for the 7 patients with a second biopsy.

\*Among patients with detectable HIV-RNA. \*\*Among patients undergoing concomitant treatment. ¥Among patients with detectable HBV-DNA. ¶Viral load for the only patient with detectable HBV-DNA is given.